Cancer Research Prevention Award  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, Y.
Right arrow Articles by Sadée, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, Y.
Right arrow Articles by Sadée, W.
[Cancer Research 65, 7446-7454, August 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance

Ying Huang1, Zunyan Dai1, Catalin Barbacioru2 and Wolfgang Sadée1

1 Program of Pharmacogenomics, Department of Pharmacology, Comprehensive Cancer Center and 2 Department of Biomedical Informatics, College of Medicine and Public Health, Ohio State University, Columbus, Ohio

Requests for reprints: Wolfgang Sadée, Program in Pharmacogenomics, Department of Pharmacology, Comprehensive Cancer Center, College of Medicine and Public Health, Ohio State University, 5072 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210-1239. Phone: 614-292-5593; Fax: 614-292-7232; E-mail: sadee-1{at}medctr.osu.edu.

SLC7A11 (xCT), together with SLC3A2 (4F2hc), encodes the heterodimeric amino acid transport system xc, which mediates cystine-glutamate exchange and thereby regulates intracellular glutathione levels. We used microarrays to analyze gene expression of transporters in 60 human cancer cell lines used by the National Cancer Institute for drug screening (NCI-60). The expression of SLC7A11 showed significant correlation with that of SLC3A2 (r = 0.66), which in turn correlated with SLC7A5 (r = 0.68), another known partner for SLC3A2, and with T1A-2 (r = 0.60; all P < 0.0001). Linking expression of SLC7A11 with potency of 1,400 candidate anticancer drugs identified 39 showing positive correlations, e.g., amino acid analogue, L-alanosine, and 296 with negative correlations, e.g., geldanamycin. However, no significant correlation was observed with the geldanamycin analogue 17-allylamino, 17-demethoxygeldanamycin (17-AAG). Inhibition of transport system xc with glutamate or (S)-4-carboxyphenylglycine in lung A549 and HOP-62, and ovarian SK-OV-3 cells, reduced the potency of L-alanosine and lowered intracellular glutathione levels. This further resulted in increased potency of geldanamycin, with no effect on 17-AAG. Down-regulation of SLC7A11 by small interfering RNA affected drug potencies similarly to transport inhibitors. The inhibitor of {gamma}-glutamylcysteine synthetase, buthionine sulfoximine, also decreased intracellular glutathione levels and enhanced potency of geldanamycin, but did not affect L-alanosine. These results indicate that SLC7A11 mediates cellular uptake of L-alanosine but confers resistance to geldanamycin by supplying cystine for glutathione maintenance. SLC7A11 expression could serve as a predictor of cellular response to L-alanosine and glutathione-mediated resistance to geldanamycin, yielding a potential target for increasing chemosensitivity to multiple drugs.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
W. Guo, P. Reigan, D. Siegel, and D. Ross
Enzymatic Reduction and Glutathione Conjugation of Benzoquinone Ansamycin Heat Shock Protein 90 Inhibitors: Relevance for Toxicity and Mechanism of Action
Drug Metab. Dispos., October 1, 2008; 36(10): 2050 - 2057.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. E. Blower, J.-H. Chung, J. S. Verducci, S. Lin, J.-K. Park, Z. Dai, C.-G. Liu, T. D. Schmittgen, W. C. Reinhold, C. M. Croce, et al.
MicroRNAs modulate the chemosensitivity of tumor cells
Mol. Cancer Ther., January 1, 2008; 7(1): 1 - 9.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Liu, P. E. Blower, A.-N. Pham, J. Fang, Z. Dai, C. Wise, B. Green, C. H. Teitel, B. Ning, W. Ling, et al.
Cystine-Glutamate Transporter SLC7A11 Mediates Resistance to Geldanamycin but Not to 17-(Allylamino)-17-demethoxygeldanamycin
Mol. Pharmacol., December 1, 2007; 72(6): 1637 - 1646.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. E. Blower, J. S. Verducci, S. Lin, J. Zhou, J.-H. Chung, Z. Dai, C.-G. Liu, W. Reinhold, P. L. Lorenzi, E. P. Kaldjian, et al.
MicroRNA expression profiles for the NCI-60 cancer cell panel
Mol. Cancer Ther., May 1, 2007; 6(5): 1483 - 1491.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
Y. Sakakura, H. Sato, A. Shiiya, M. Tamba, J.-i. Sagara, M. Matsuda, N. Okamura, N. Makino, and S. Bannai
Expression and function of cystine/glutamate transporter in neutrophils
J. Leukoc. Biol., April 1, 2007; 81(4): 974 - 982.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.